Rapport Therapeutics Funding: $100M Raised, Series A (2023)
Rapport Therapeutics is a Biotech company based in Boston. It has raised $100M in total funding. Latest round: Series A.
Rapport Therapeutics funding overview
Rapport Therapeutics is a Biotech company based in Boston. Rapport Therapeutics has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in March 2023. The round record for Rapport Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation-JJDC, Inc.. 3 distinct backers are named across the disclosed rounds.
Rapport Therapeutics at a glance
Total raised
$100M
Latest round
Series A
Latest round date
March 2023
Industry
Biotech
Headquarters
Boston
Notable investors
Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation-JJDC, Inc.
Frequently asked about Rapport Therapeutics funding
How much has Rapport Therapeutics raised?
Rapport Therapeutics has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Rapport Therapeutics?
Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation-JJDC, Inc. are named among the investors backing Rapport Therapeutics.
What was the latest Rapport Therapeutics funding round?
The most recent disclosed round is a Series A, announced in March 2023.
Where is Rapport Therapeutics based?
Rapport Therapeutics is based in Boston.
What sector does Rapport Therapeutics operate in?
Rapport Therapeutics is tracked under Biotech from Boston, with $100M in disclosed funding.
When did Rapport Therapeutics last raise?
The last disclosed Rapport Therapeutics round closed in March 2023 at Series A.
Every Rapport Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in Boston at a similar stage.
